Home » Stocks » CPRX

Catalyst Pharmaceuticals, Inc. (CPRX)

Stock Price: $5.77 USD -0.03 (-0.52%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $5.70 -0.07 (-1.21%) Jun 22, 5:31 PM
Market Cap 590.21M
Revenue (ttm) 120.14M
Net Income (ttm) 72.22M
Shares Out 103.81M
EPS (ttm) 0.68
PE Ratio 8.49
Forward PE 15.92
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $5.77
Previous Close $5.80
Change ($) -0.03
Change (%) -0.52%
Day's Open 5.79
Day's Range 5.68 - 5.80
Day's Volume 491,209
52-Week Range 2.88 - 5.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada

2 weeks ago - GlobeNewsWire

CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, devel...

1 month ago - GlobeNewsWire

Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.

1 month ago - Zacks Investment Research

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

-Firdapse® Q1 2021 Net Revenues of $30.2 Million

1 month ago - GlobeNewsWire

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Other stocks mentioned: HRMY, MYOV, PRTA
1 month ago - Zacks Investment Research

Catalyst is facing its fair share of classic pharma challenges.

1 month ago - The Motley Fool

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, deve...

1 month ago - GlobeNewsWire

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

With solid revenue growth, these stocks have the potential to more than triple over the next few years.

Other stocks mentioned: CORT, SUPN
2 months ago - The Motley Fool

CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...

3 months ago - GlobeNewsWire

To increase one's chances of beating the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

Other stocks mentioned: FKWL, IDT
3 months ago - GuruFocus

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

3 months ago - Zacks Investment Research

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million

3 months ago - GlobeNewsWire

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

Other stocks mentioned: ATNX, BLU, NBEV, OPK, SPPI, UEC
3 months ago - InvestorPlace

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing in...

3 months ago - GlobeNewsWire

CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...

4 months ago - GlobeNewsWire

Penny stocks are low price for a reason. Most presume they're destined for bankruptcy.

Other stocks mentioned: ABEV, AUY, BBD, NWG, WTI
4 months ago - InvestorPlace

Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by m...

Other stocks mentioned: TXMD
4 months ago - 24/7 Wall Street

Investors can start the new year off right by digging into these three small but fiery stocks.

Other stocks mentioned: OGI, VXRT
5 months ago - The Motley Fool

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

5 months ago - Zacks Investment Research

Investors focused on assets with high returns may want to consider the following non-cyclical stocks, as their earnings yields (as calculated through Joel Greenblatt's method) are outperforming the S&P ...

Other stocks mentioned: NRG, TSN
5 months ago - GuruFocus

CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...

5 months ago - GlobeNewsWire

Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and price-to-sales...

5 months ago - Seeking Alpha

Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability t...

Other stocks mentioned: CODX, QDEL
5 months ago - Seeking Alpha

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BDSI, BMRN, INVA, NVAX, VRTX, VXRT, VYGR
6 months ago - Investopedia

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

7 months ago - Zacks Investment Research

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

- Firdapse® Third Quarter Net Revenues of $ 29. 2 Million

7 months ago - GlobeNewsWire

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

7 months ago - Zacks Investment Research

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. The post Despite Legal Drama, Catalyst Pharmaceuticals Looks ...

7 months ago - InvestorPlace

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...

7 months ago - GlobeNewsWire

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...

Other stocks mentioned: PRDO, SBR, VNDA, XBIT
7 months ago - GuruFocus

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

8 months ago - InvestorPlace

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...

8 months ago - GlobeNewsWire

Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds

8 months ago - Seeking Alpha

Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®

8 months ago - GlobeNewsWire

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adop...

8 months ago - GlobeNewsWire

Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit.

8 months ago - 24/7 Wall Street

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research

Catalyst can't seem to catch a break in the clinic these days.

9 months ago - The Motley Fool

Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.

9 months ago - Zacks Investment Research

Notice of Application for Judicial Review Filed Today in the Federal Court of Canada Notice of Application for Judicial Review Filed Today in the Federal Court of Canada

9 months ago - GlobeNewsWire

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthe... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2006
CEO
Patrick McEnany
Employees
74
Stock Exchange
NASDAQ
Ticker Symbol
CPRX
Full Company Profile

Financial Performance

In 2020, CPRX's revenue was $119.07 million, an increase of 16.39% compared to the previous year's $102.31 million. Earnings were $74.98 million, an increase of 135.24%.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 29.98% from the latest price.

Price Target
$7.50
(29.98% upside)
Analyst Consensus: Buy